



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

November 21, 2018

BSE Limited

Department of Corporate Services
Listing Department,
PJ Tower, Dalal Street,
Mumbai 400001, India
Scrip Code: **524816**
Kind Attn: Mr. Raghavendra Bhat

National Stock Exchange of India Ltd

Listing Department,
'Exchange Plaza', C-1, Block-G,
Bandra Kurla Complex, Bandra (East),
Mumbai 400051, India
Scrip Code: **NATCOPHARM**
Kind Attn: Ms. Aarti Surve

Sir/Madam,

Sub: Buy Back of fully paid-up equity shares of face value of Rs.2/- each (the "Equity Shares") of **Natco Pharma Limited** (the "Company") under the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018 (the "Buy-back Regulations")

With reference to the captioned subject matter, the Company hereby submits the daily report pursuant to regulation 18(i) of the Buy-Back Regulations regarding the Equity Shares bought-back on 21/11/2018.

| Name of the Broker | Number of Equity Shares Bought Back on (21/11/2018) | | Total shares bought back on 21/11/2018 | Average Price of Acquisition (Rs.) |
|--|---|-------|--|------------------------------------|
| | BSE | NSE | | |
| Axis Capital Limited | 4000 | 23300 | | (Price)* |
| Total (A) | 4000 | 23300 | 27300 | 732.0043 |
| Cumulative Equity Shares bought as on Yesterday (B) | | | | 56222 |
| Less: Quantity Closed Out Today (C) | | | | 0 |
| Quantity Closed Out as on Yesterday (D) | | | | 0 |
| Total Quantity closed out (C+D=E) | | | | 0 |
| Total Equity Shares bought back as on 20/11/2018 (A) + (B) - (E) | | | | 83522 |

Notes:

- *Excludes Transaction Costs
- Previous reporting period is the day before the current reporting date when the Company has last filed report on Equity Shares bought back 20/11/2018
- Current reporting period is the day on which this report is being filed with the stock exchanges, being 21/11/2018.
- The above information is subject to settlement as per the existing rules for secondary market transactions of the Stock Exchanges and verification of Equity Shares bought back, where applicable.

For Natco Pharma Limited

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)